Glioblastomas are the most common primary brain tumor and the most lethal. Current glioblastoma therapy provides only palliation and these cancers are universally fatal. Although the concept of a tumor cell hierarchy remains controversial, increasing evidence supports the notion that subgroups of stem-like cancer cells contribute to tumor growth. These cancer stem cells stimulate the malignancy of tumor growth through preferential resistance to conventional therapies, stimulation of angiogenesis, and invasion into normal tissues. A central unexplained observation in the cancer stem cell hypothesis is the reestablishment of a cellular hierarchy despite growth advantages of the stem-like cells. Cancer stem cells express pro-differentiation factors, including bone morphogenetic proteins, which may promote the maintenance of differentiated tumor cells that provide signals in support of the cancer stem cells (e.g. Notch ligands, interleukin-6, and laminins). To determine potential microenvironmental interactions that maintain the cellular hierarchy, we interrogated secreted regulators of cellular differentiation that are associated with the cellular hierarchy. We find that glioblastoma stem cells express secreted antagonists of differentiation signals to maintain their growth. Further, forced expression of these molecules in non-stem tumor cells promotes stem-like features. The simultaneous expression of differentiating signals and their inhibitors may create tissue patterning with stem-like and differentiated populations, phenocopying development. As there is an association between expression of anti-differentiation signals and poor glioblastoma patient outcome, we hypothesize that targeting secreted inhibitors of microenvironmental differentiation cues may offer potential therapeutic benefit. The tumor microenvironment provides instructive cues to maintain the cellular hierarchy in both normal and neoplastic tissues;we are therefore developing a set of techniques to interrogate the cellular hierarchy in relevant microenvironments while representing appropriate molecular tumor phenotypes. Overall, this study will examine in vivo response of tumor cells to environmental influences such as bone morphogenic protein antagonists on the self-renewal and maintenance of stem cell-like tumor cells within their niche. Successful execution of this collaborative scientific endeavor promises to bring important new scientific insights into cancer biology, and may have profound implications for glioblastoma treatment paradigms.

Public Health Relevance

Glioblastoma is one of the most lethal of all human cancers with a need to develop novel therapies that disrupt mechanisms that maintain tumor growth. These tumors contain cells similar to normal stem cells that display resistance to current treatments. In the proposed studies, we will investigate the interaction between signals that stimulate differentiation and those that protect cells from differentiation that may contribute to these stem-like cancer cells.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA171652-01A1
Application #
8786649
Study Section
Tumor Progression and Metastasis Study Section (TPM)
Program Officer
Snyderwine, Elizabeth G
Project Start
2014-08-15
Project End
2019-07-31
Budget Start
2014-08-15
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$420,976
Indirect Cost
$155,376
Name
Cleveland Clinic Lerner
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
135781701
City
Cleveland
State
OH
Country
United States
Zip Code
44195
Dermawan, Josephine Kam Tai; Hitomi, Masahiro; Silver, Daniel J et al. (2016) Pharmacological Targeting of the Histone Chaperone Complex FACT Preferentially Eliminates Glioblastoma Stem Cells and Prolongs Survival in Preclinical Models. Cancer Res 76:2432-42
Hubert, Christopher G; Rivera, Maricruz; Spangler, Lisa C et al. (2016) A Three-Dimensional Organoid Culture System Derived from Human Glioblastomas Recapitulates the Hypoxic Gradients and Cancer Stem Cell Heterogeneity of Tumors Found In Vivo. Cancer Res 76:2465-77
Xie, Qi; Wu, Qiulian; Kim, Leo et al. (2016) RBPJ maintains brain tumor-initiating cells through CDK9-mediated transcriptional elongation. J Clin Invest 126:2757-72
Mack, Stephen C; Hubert, Christopher G; Miller, Tyler E et al. (2016) An epigenetic gateway to brain tumor cell identity. Nat Neurosci 19:10-9
Ahluwalia, Manmeet S; Rich, Jeremy N (2015) Growth Factor Receptor Fusions Predict Therapeutic Sensitivity. Clin Cancer Res 21:3105-7
Mack, Stephen C; Rich, Jeremy N; Scacheri, Peter C (2015) ""PEAR-ing"" Genomic and Epigenomic Analyses for Cancer Gene Discovery. Cancer Discov 5:1018-20
Rivera, M; Wu, Q; Hamerlik, P et al. (2015) Acquisition of meiotic DNA repair regulators maintain genome stability in glioblastoma. Cell Death Dis 6:e1732
Xie, Qi; Wu, Qiulian; Mack, Stephen C et al. (2015) CDC20 maintains tumor initiating cells. Oncotarget 6:13241-54
Schonberg, David L; Miller, Tyler E; Wu, Qiulian et al. (2015) Preferential Iron Trafficking Characterizes Glioblastoma Stem-like Cells. Cancer Cell 28:441-55
Xie, Qi; Wu, Qiulian; Horbinski, Craig M et al. (2015) Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci 18:501-10

Showing the most recent 10 out of 13 publications